SAMN03290941
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.600
- E2F_TARGETS+0.500
- G2M_CHECKPOINT+0.400
- FATTY_ACID_METABOLISM+0.300
- MITOTIC_SPINDLE+0.300
- MYC_TARGETS_V1+0.300
- PROTEIN_SECRETION+0.300
- ADIPOGENESIS+0.200
- DNA_REPAIR+0.200
- MTORC1_SIGNALING+0.200
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.600
- ALLOGRAFT_REJECTION-0.500
- ANGIOGENESIS-0.500
- IL6_JAK_STAT3_SIGNALING-0.500
- INFLAMMATORY_RESPONSE-0.500
- INTERFERON_ALPHA_RESPONSE-0.500
- INTERFERON_GAMMA_RESPONSE-0.500
- KRAS_SIGNALING_UP-0.400
- TNFA_SIGNALING_VIA_NFKB-0.400
- APICAL_JUNCTION-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SAMN03290953 | — | — | 0.973 |
| 2 | SAMN03290933 | — | — | 0.937 |
| 3 | MDT-AP-1214 | Med | Medulloblastoma | 0.903 |
| 4 | 49319954-0844-4fbc-a931-df0e4cdbcb14 | — | — | 0.900 |
| 5 | TCGA-B6-A0X5-01A-21R-A109-07 | — | B | 0.898 |
| 6 | f8d9864e-e148-4e60-9d9d-3df2897050cd | — | — | 0.894 |
| 7 | 64935b9c-623d-40d4-bd89-f2af006b1f92 | — | — | 0.885 |
| 8 | AUR-AERX-TTM1-A-1-1-R-A742-41 | — | C | 0.883 |
| 9 | 13649cf2-1dc4-408f-9063-31a2b9bb7157 | — | — | 0.882 |
| 10 | SRR23303743 | — | — | 0.882 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.600 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.500 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.400 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.300 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.300 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.300 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.300 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.200 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.200 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.200 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.200 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.100 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.100 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.100 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.100 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.100 | Temsirolimus | — uncovered |
| PEROXISOME | 0.100 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.100 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.100 | Inavolisib | — uncovered |